SCHEMBL4035227

SCHEMBL4035227

O=C(CCl)NCc1ccc(Cl)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.68
MEN1 O00255 4/20 0.68
CYP2C9 P11712 1/20 0.63
CYP2C19 P33261 1/20 0.63
RAB9A P51151 3/20 0.62
ALDH1A1 P00352 2/20 0.62
HPGD P15428 2/20 0.62
NPC1 O15118 2/20 0.62
GAA P10253 1/20 0.60
POLB P06746 2/20 0.55
CA12 O43570 1/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
CA9 Q16790 1/20 0.55
TEAD1 P28347 1/20 0.54
YAP1 P46937 1/20 0.54
TEAD4 Q15561 1/20 0.54
TEAD2 Q15562 1/20 0.54
ERCC1 P07992 1/20 0.54
ERCC4 Q92889 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9798143 0.86 ALDH1A1 (0.58) KMT2AMEN1CYP2C9CYP2C19RAB9A
SCHEMBL17372509 0.85 HPGD (0.68) KMT2AMEN1CYP2C9CYP2C19RAB9A
SCHEMBL10692807 0.84 KMT2A (0.68) KMT2AMEN1CYP2C9CYP2C19RAB9A
SCHEMBL16082991 0.84 ALDH1A1 (0.83) KMT2AMEN1CYP2C9CYP2C19RAB9A
SCHEMBL23565002 0.82 KMT2A (0.66) KMT2AMEN1CYP2C9CYP2C19RAB9A
SCHEMBL5574769 0.82 LMNA (0.66) KMT2AMEN1CYP2C19RAB9AHPGD
SCHEMBL4586604 0.82 KMT2A (0.66) KMT2AMEN1CYP2C9CYP2C19RAB9A
SCHEMBL22500066 0.82 L3MBTL1 (0.62) KMT2AMEN1RAB9AALDH1A1HPGD
SCHEMBL1709315 0.82 HPGD (0.70) KMT2AMEN1CYP2C9CYP2C19RAB9A
SCHEMBL1274911 0.82 LMNA (0.68) KMT2ARAB9AALDH1A1HPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5834514-A INHIBITORS OF INTERLEUKIN-1B CONVERTING ENZYME, TREATMENT OF INFLAMMATORY AND IMMUNE BASED DISEASES OF THE LUNGS, CENTRAL NERVOUS SYSTEM AND CONNECTIVE TISSUES VERTEX PHARMACEUTICALS, INCORPORATED (US) 1998-11-10 US claimed
EP-0758891-A4 HALOMETHYL AMIDES AS IL-1-g(b) PROTEASE INHIBITORS SANOFI WINTHROP INC (US) 1997-12-03 EP claimed
EP-0758891-A1 HALOMETHYL AMIDES AS IL-1$g(b) PROTEASE INHIBITORS SANOFI WINTHROP, INC. (US) 1997-02-26 EP claimed
WO-1995029672-A1 HALOMETHYL AMIDES AS IL-1β PROTEASE INHIBITORS SANOFI WINTHROP, INC. (US) 1995-11-09 WO claimed
EP-4698170-A1 GLYCINAMIDE DERIVATIVES FOR USE IN THE TREATMENT OF SALMONELLOSIS Eberhard-Karls-Universität Tübingen (DE) 2026-02-25 EP disclosed
WO-2024218333-A1 GLYCINAMIDE DERIVATIVES FOR USE IN THE TREATMENT OF SALMONELLOSIS EBERHARD KARLS UNIVERSITÄT TÜBINGEN MEDIZINISCHE FAKULTÄT (DE) 2024-10-24 WO disclosed
WO-2009125191-A1 BENZENE DERIVATIVES UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2009-10-15 WO disclosed
EP-1806346-B1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors CV THERAPEUTICS INC (US) 2009-07-22 EP disclosed
US-7550458-B2 Tricycloundecane compounds useful as modulators of nuclear hormone receptor function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-23 US disclosed
US-7550458-B2 Tricycloundecane compounds useful as modulators of nuclear hormone receptor function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-23 US disclosed
US-7550458-B2 Tricycloundecane compounds useful as modulators of nuclear hormone receptor function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-23 US disclosed
US-7407960-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2008-08-05 US disclosed
US-6730682-B2 HERPES VIRUS PHARMACIA & UPJOHN COMPANY 2004-05-04 US disclosed
EP-1363907-A2 HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-11-26 EP disclosed
US-20020019397-A1 Heterocycle carboxamides as antiviral agents PHARMACIA & UPJOHN COMPANY 2002-02-14 US disclosed
WO-2002004443-A2 HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2002-01-17 WO disclosed
US-5834514-A INHIBITORS OF INTERLEUKIN-1B CONVERTING ENZYME, TREATMENT OF INFLAMMATORY AND IMMUNE BASED DISEASES OF THE LUNGS, CENTRAL NERVOUS SYSTEM AND CONNECTIVE TISSUES VERTEX PHARMACEUTICALS, INCORPORATED (US) 1998-11-10 US disclosed
EP-0758891-A4 HALOMETHYL AMIDES AS IL-1-g(b) PROTEASE INHIBITORS SANOFI WINTHROP INC (US) 1997-12-03 EP disclosed
EP-0758891-A1 HALOMETHYL AMIDES AS IL-1$g(b) PROTEASE INHIBITORS SANOFI WINTHROP, INC. (US) 1997-02-26 EP disclosed
WO-1995029672-A1 HALOMETHYL AMIDES AS IL-1β PROTEASE INHIBITORS SANOFI WINTHROP, INC. (US) 1995-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019397-A1 Heterocycle carboxamides as antiviral agents ZC3HAV1, ZC3HAV1L, HDAC1 KMT2A 993/4885MEN1 2250/4885CYP2C9 1284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.